Advitech's new project, within its business intelligence activities, is a collection of Reports focused on the active pharmaceutical ingredients (APIs) world: APIsTRENDS. The first issue of the APIsTrends collection is CDMO Benchmarking Report - Baseline analysis.
A Benchmarking study for the CDMO sector, starting with a baseline analysis of 2016 data where two main studies were planned:
New coming updated editions will enable to outline the main trends in this industrial sector, but this first CDMO Benchmarking Report will be an indispensable starting point to evaluate the market value of active pharmaceuticals ingredients (APIs) which is not so visible.
The global contract development and manufacturing organization (CDMO) market is currently experiencing a constant growth and increasing interest in the healthcare world. The rise of CDMOs is a key aspect of the pharmaceutical industry's evolution over the past decades, where two-thirds of pharmaceutical manufacturing is outsourced. However, despite the wealth of information publicly available, it can be difficult to extrapolate the data required to make informed decisions about outsourced manufacturing, or investments in this sector. To meet this need address we at Advitech have decided to conduct the first benchmarking study on API CDMOs, starting by a baseline analysis according to 2016 data. The work is structured in two parts: one with an evaluation of the reference market value of drug substances produced by CDMOs. In fact, while the market value of finished dosage forms (FDFs) manufactured by CDMOs can be relatively easily assessed, values for APIs are not as visible. Therefore, to obtain an estimated value of the market pertaining to the subsequent benchmarking study, we performed a series of extrapolations from a range of publicly available and published data. The analysis provides an insight, placing an actual figure on the global market for drug substance APIs. The second part is a benchmarking study where 27 companies were chosen due to their well-established role as contract manufacturers and small molecule API capabilities. The selected companies were mainly headquartered in Europe or in the US, although two best-in-class companies in Asia were also included to provide additional perspective.
Advitech NEW report is focused on the latest trends in the global Contract Development and Manufacturing Organization (CDMO) market.
CDMO business models continue to evolve with CDMOs seeking to offer differentiated services or technologies, adding drug-product capabilities to existing small-molecule API expertise, or increasing investment in specialized technologies, such as high-potency manufacturing. The report details key differentiating technologies and services.
The report shows also several important trends in terms of pharmaceutical industry performance, drug development and recent new drug approvals, and the impact on the contract development and manufacturing (CDMO) market.
The focus of this analysis was to specifically examine the position of small-molecule drugs in the overall pharmaceutical market, drug development, and the impact on the strategy and business activity of CDMOs serving the small-molecule API space.
Last year Advitech selected a panel of 27 companies within the previous Baseline Analysis focused on 2016 data. These companies were chosen due to the following:
Now, with an unprecedented approach in our industry, Advitech has performed a three-year update of the same panel of companies that were considered in the Baseline Analysis as service providers in the CDMO sector for small-molecule APIs.
In a relatively short time frame, the panel has now evolved through mergers and acquisitions and rebranding activities into a new group of companies